(HCA) HCA Holdings - Ratings and Ratios
Hospital, Outpatient, Surgery, Emergency, Psychiatry
HCA EPS (Earnings per Share)
HCA Revenue
Description: HCA HCA Holdings
HCA Healthcare, Inc. (NYSE:HCA) operates a nationwide network of general-acute hospitals and a broad suite of outpatient facilities, ranging from freestanding surgery centers and urgent-care clinics to behavioral health hospitals and oncology centers. Its service portfolio spans inpatient care (including intensive-care, cardiac, and emergency services) and outpatient offerings such as radiology, laboratory, physical therapy, and physician practice management.
As of the end of FY 2023, HCA reported revenue of roughly **$15.6 billion**, with an adjusted operating margin near **7 %**-a level that reflects both the scale efficiencies of its integrated model and the cost pressures from a tight labor market. The company now runs **over 190 hospitals** and **more than 2,000 outpatient sites**, serving a patient mix that is approximately 55 % commercial, 30 % Medicare, and 15 % Medicaid.
Key economic drivers for HCA include the aging U.S. population, which is expanding demand for acute-care and chronic-disease management, and the ongoing shift toward outpatient and same-day procedures that improve throughput and reduce per-case costs. Conversely, inflation-driven labor shortages and potential regulatory changes to Medicare reimbursement pose downside risk to margins.
Given these dynamics, a thorough scenario-based valuation can help isolate the impact of payer mix shifts, labor-cost inflation, and outpatient-care growth on HCA’s future cash flows. For a deeper dive into HCA’s valuation metrics and scenario analysis, you may find the research tools on ValueRay worth exploring.
HCA Stock Overview
| Market Cap in USD | 100,510m |
| Sub-Industry | Health Care Facilities |
| IPO / Inception | 2011-03-10 |
HCA Stock Ratings
| Growth Rating | 78.8% |
| Fundamental | 74.5% |
| Dividend Rating | 56.5% |
| Return 12m vs S&P 500 | -6.52% |
| Analyst Rating | 4.08 of 5 |
HCA Dividends
| Dividend Yield 12m | 0.68% |
| Yield on Cost 5y | 2.26% |
| Annual Growth 5y | 36.07% |
| Payout Consistency | 53.8% |
| Payout Ratio | 11.6% |
HCA Growth Ratios
| Growth Correlation 3m | 90% |
| Growth Correlation 12m | 62.1% |
| Growth Correlation 5y | 90.1% |
| CAGR 5y | 28.62% |
| CAGR/Max DD 3y (Calmar Ratio) | 1.01 |
| CAGR/Mean DD 3y (Pain Ratio) | 3.42 |
| Sharpe Ratio 12m | 1.65 |
| Alpha | -9.29 |
| Beta | 1.407 |
| Volatility | 23.90% |
| Current Volume | 1638.3k |
| Average Volume 20d | 1184.9k |
| Stop Loss | 402.6 (-3%) |
| Signal | 0.06 |
Piotroski VR‑10 (Strict, 0-10) 7.5
| Net Income (5.97b TTM) > 0 and > 6% of Revenue (6% = 4.36b TTM) |
| FCFTA 0.12 (>2.0%) and ΔFCFTA 3.73pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue -0.52% (prev 1.28%; Δ -1.79pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.20 (>3.0%) and CFO 11.94b > Net Income 5.97b (YES >=105%, WARN >=100%) |
| Net Debt (45.42b) to EBITDA (14.36b) ratio: 3.16 <= 3.0 (WARN <= 3.5) |
| Current Ratio 0.98 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (241.9m) change vs 12m ago -8.39% (target <= -2.0% for YES) |
| Gross Margin 15.24% (prev 14.90%; Δ 0.34pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 124.4% (prev 119.1%; Δ 5.25pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 5.07 (EBITDA TTM 14.36b / Interest Expense TTM 2.16b) >= 6 (WARN >= 3) |
Altman Z'' 0.92
| (A) -0.01 = (Total Current Assets 15.56b - Total Current Liabilities 15.94b) / Total Assets 59.54b |
| (B) -0.07 = Retained Earnings (Balance) -4.09b / Total Assets 59.54b |
| (C) 0.19 = EBIT TTM 10.94b / Avg Total Assets 58.46b |
| (D) -0.07 = Book Value of Equity -4.39b / Total Liabilities 60.77b |
| Total Rating: 0.92 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 74.47
| 1. Piotroski 7.50pt = 2.50 |
| 2. FCF Yield 5.00% = 2.50 |
| 3. FCF Margin 10.03% = 2.51 |
| 4. Debt/Equity -10.55 = -2.50 |
| 5. Debt/Ebitda 3.16 = -1.98 |
| 6. ROIC - WACC (= 13.12)% = 12.50 |
| 7. RoE -189.6% = -2.50 |
| 8. Rev. Trend 97.87% = 7.34 |
| 9. EPS Trend 82.15% = 4.11 |
What is the price of HCA shares?
Over the past week, the price has changed by -4.25%, over one month by +2.65%, over three months by +9.31% and over the past year by +5.75%.
Is HCA Holdings a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of HCA is around 457.16 USD . This means that HCA is currently undervalued and has a potential upside of +10.12% (Margin of Safety).
Is HCA a buy, sell or hold?
- Strong Buy: 13
- Buy: 2
- Hold: 9
- Sell: 1
- Strong Sell: 0
What are the forecasts/targets for the HCA price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 403.8 | -2.7% |
| Analysts Target Price | 403.8 | -2.7% |
| ValueRay Target Price | 507.3 | 22.2% |
Last update: 2025-10-06 02:05
HCA Fundamental Data Overview
P/E Trailing = 18.0403
P/E Forward = 14.9701
P/S = 1.3826
P/B = 293.44
P/EG = 1.2217
Beta = 1.407
Revenue TTM = 72.70b USD
EBIT TTM = 10.94b USD
EBITDA TTM = 14.36b USD
Long Term Debt = 39.38b USD (from longTermDebt, last quarter)
Short Term Debt = 5.10b USD (from shortTermDebt, last quarter)
Debt = 46.36b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 45.42b USD (from netDebt column, last quarter)
Enterprise Value = 145.93b USD (100.51b + Debt 46.36b - CCE 939.0m)
Interest Coverage Ratio = 5.07 (Ebit TTM 10.94b / Interest Expense TTM 2.16b)
FCF Yield = 5.00% (FCF TTM 7.29b / Enterprise Value 145.93b)
FCF Margin = 10.03% (FCF TTM 7.29b / Revenue TTM 72.70b)
Net Margin = 8.21% (Net Income TTM 5.97b / Revenue TTM 72.70b)
Gross Margin = 15.24% ((Revenue TTM 72.70b - Cost of Revenue TTM 61.62b) / Revenue TTM)
Gross Margin QoQ = 15.95% (prev 15.58%)
Tobins Q-Ratio = 2.45 (Enterprise Value 145.93b / Total Assets 59.54b)
Interest Expense / Debt = 1.23% (Interest Expense 568.0m / Debt 46.36b)
Taxrate = 21.70% (524.0m / 2.42b)
NOPAT = 8.57b (EBIT 10.94b * (1 - 21.70%))
Current Ratio = 0.98 (Total Current Assets 15.56b / Total Current Liabilities 15.94b)
Debt / Equity = -10.55 (negative equity) (Debt 46.36b / totalStockholderEquity, last quarter -4.39b)
Debt / EBITDA = 3.16 (Net Debt 45.42b / EBITDA 14.36b)
Debt / FCF = 6.23 (Net Debt 45.42b / FCF TTM 7.29b)
Total Stockholder Equity = -3.15b (last 4 quarters mean from totalStockholderEquity)
RoA = 10.03% (Net Income 5.97b / Total Assets 59.54b)
RoE = -189.6% (negative equity) (Net Income TTM 5.97b / Total Stockholder Equity -3.15b)
RoCE = 30.19% (EBIT 10.94b / Capital Employed (Equity -3.15b + L.T.Debt 39.38b))
RoIC = 21.09% (NOPAT 8.57b / Invested Capital 40.62b)
WACC = 7.97% (E(100.51b)/V(146.87b) * Re(11.20%) + D(46.36b)/V(146.87b) * Rd(1.23%) * (1-Tc(0.22)))
Discount Rate = 11.20% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -5.55%
[DCF Debug] Terminal Value 69.09% ; FCFE base≈6.33b ; Y1≈6.85b ; Y5≈8.49b
Fair Price DCF = 388.2 (DCF Value 90.83b / Shares Outstanding 234.0m; 5y FCF grow 9.20% → 3.0% )
EPS Correlation: 82.15 | EPS CAGR: 22.32% | SUE: 1.42 | # QB: 2
Revenue Correlation: 97.87 | Revenue CAGR: 8.22% | SUE: 0.34 | # QB: 0
Additional Sources for HCA Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle